1. Home
  2. KMT vs MLYS Comparison

KMT vs MLYS Comparison

Compare KMT & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kennametal Inc.

KMT

Kennametal Inc.

HOLD

Current Price

$35.51

Market Cap

2.9B

Sector

Industrials

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$23.42

Market Cap

2.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KMT
MLYS
Founded
1938
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.9B
2.4B
IPO Year
1994
2023

Fundamental Metrics

Financial Performance
Metric
KMT
MLYS
Price
$35.51
$23.42
Analyst Decision
Hold
Strong Buy
Analyst Count
6
6
Target Price
$36.00
$48.67
AVG Volume (30 Days)
1.5M
1.0M
Earning Date
05-06-2026
03-12-2026
Dividend Yield
2.22%
N/A
EPS Growth
N/A
37.43
EPS
0.74
N/A
Revenue
$1,966,845,000.00
N/A
Revenue This Year
$14.45
N/A
Revenue Next Year
$7.95
N/A
P/E Ratio
$48.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.30
$10.44
52 Week High
$42.03
$47.65

Technical Indicators

Market Signals
Indicator
KMT
MLYS
Relative Strength Index (RSI) 39.22 29.66
Support Level $33.93 $13.42
Resistance Level $41.89 $31.09
Average True Range (ATR) 1.84 1.77
MACD -0.63 -0.26
Stochastic Oscillator 8.25 9.72

Price Performance

Historical Comparison
KMT
MLYS

About KMT Kennametal Inc.

Kennametal Inc is a manufacturer of metalworking tools and wear-resistant engineered components and coatings. The company operates in two business segments; Metal Cutting and Infrastructure. It generates maximum revenue from the Metal Cutting segment. The Metal Cutting segment develops and manufactures high-performance tooling and metal cutting products and services and offers an assortment of standard and custom metal cutting solutions to diverse end markets, including aerospace, general engineering, energy, and transportation. Geographically, it derives maximum revenue from the United States and the rest from Germany, China, Canada, India, Italy, and other countries.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: